ArticleOncology letters2026
Comprehensive treatment for two patients with small cell neuroendocrine carcinoma of the liver: A case report and literature review.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic small cell neuroendocrine carcinoma (HSCNEC) is a rare and aggressive malignancy with a poor prognosis. The marked heterogeneity of neuroendocrine carcinomas, along with their predominantly non-functional nature and the absence of specific biomarkers, poses substantial diagnostic challenges and leads to complex, varied treatment pathways. Owing to its rarity and the scarcity of clinical evidence, treatment options for HSCNEC remain limited, often resulting in unsatisfactory outcomes. Recent advances, however, underscore transcatheter arterial chemoembolization (TACE) combined with targeted immunotherapy as a promising strategy for HSCNEC. A 76-year-old male patient was admitted for intermittent right upper abdominal pain lasting 3 months. Medical history included hepatitis B for 50 years, hypertension for 20 years, diabetes mellitus for 10 years and coronary artery disease for 5 years. A 58-year-old male was admitted to the hospital one week after discovering a hepatic space-occupying lesion, following 1 month of upper abdominal discomfort. The patient had a history of hepatitis B for >10 years. Both patients underwent tumor puncture biopsy and the pathological diagnosis confirmed the presence of SCNEC of the liver. The first patient received TACE but declined subsequent combined targeted immunotherapy and died 3 months later. By contrast, the second patient underwent multiple sessions of TACE along with targeted immunotherapy, resulting in a significant improvement in quality of life. This patient is currently under regular follow-up and is able to lead a normal life and work. HSCNEC is a rare type of intrahepatic neuroendocrine tumor. For cases that are not amenable to surgical resection, TACE combined with targeted immunotherapy may be considered. This comprehensive treatment approach can significantly enhance the effectiveness of therapy and prolong overall survival for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.